Molecular imaging of p53 signal pathway in lung cancer cell cycle arrest induced by cisplatin

Molecular Carcinogenesis

Volumn 52, Issue 11, 2013, Pages 900-907

  Wang, Shenxu ^a   Li, Weijie ^a   Xue, Zengfu ^a   Lu, Yuanyuan ^a   Narsinh, Kazim ^b   Fan, Weiwei ^a   Li, Xiujuan ^a   Bu, Qingting ^a   Wang, Fu ^c   Liang, Jimin ^c   Wu, Kaichun ^a   Cao, Feng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c XIDIAN UNIVERSITY   (China)

Author keywords

Cell cycle; Cisplatin; Lung cancer; Molecular imaging; P53

Indexed keywords

CISPLATIN; CYCLIN A2; PROTEIN P53; TRANSCRIPTION FACTOR E2F1; ANTINEOPLASTIC AGENT;

ACTIN FILAMENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL COUNT; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; COMPARATIVE STUDY; DNA REPLICATION; DNA RESPONSIVE ELEMENT; DOWN REGULATION; DRUG CYTOTOXICITY; FLUORESCENCE IMAGING; GENE EXPRESSION; LUNG ADENOCARCINOMA; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; RNA SEQUENCE; STRUCTURAL GENE; TANDEM REPEAT; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL CYCLE CHECKPOINT; DRUG EFFECTS; HUMAN; LUNG; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CISPLATIN; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MOLECULAR IMAGING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84886302360     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21930     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-130.
2. Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 2005; 10:1-10.
3. Fleming S, Lucas F, Schofield M. A therapeutic area review of oncology products and players. Expert Opin Emerg Drugs 2001; 6:317-329.
4. Cohen GL, Bauer WR, Barton JK, Lippard SJ. Binding of cis- and trans-dichlorodiammineplatinum(II) to DNA: Evidence for unwinding and shortening of the double helix. Science 1979; 203:1014-1016.
5. Douillard JY, Eckardt J, Scagliotti GV. Challenging the platinum combinations in the chemotherapy of NSCLC. Lung Cancer 2002; 38:21-28.
6. Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chem Rev 1999; 99:2451-2466.
7. Levine AJ. p53, The cellular gatekeeper for growth and division. Cell 1997; 88:323-331.
8. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402-412.
9. Inoue A, Narumi K, Matsubara N, et al. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett 2000; 157:105-112.
10. Oliver TG, Mercer KL, Sayles LC, et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 2010; 24:837-852.
11. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4:307-320.
12. Liu H, Patel MR, Prescher JA, et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci USA 2010; 107:18115-18120.
13. Fushiki H, Kanoh-Azuma T, Katoh M, et al. Quantification of mouse pulmonary cancer models by microcomputed tomography imaging. Cancer Sci 2009; 100:1544-1549.
14. Jin F, Zhao L, Guo YJ, et al. Influence of etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells. Brain Res 2010; 1336:103-111.
15. 11C]-choline. Q J Nucl Med Mol Imaging 2009; 53:144-156.
16. Conesa A, Gotz S, Garcia-Gomez JM, Terol J, Talon M, Robles M. Blast2GO: A universal tool for annotation, visualization and analysis in functional genomics research. Bioinformatics 2005; 21:3674-3676.
17. Beckmann N, Mueggler T, Allegrini PR, Laurent D, Rudin M. From anatomy to the target: Contributions of magnetic resonance imaging to preclinical pharmaceutical research. Anat Rec 2001; 265:85-100.
18. Chenevert TL, et al. Diffusion magnetic resonance imaging: An early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000; 92:2029-2036.
19. Moffat BA, et al. Diffusion imaging for evaluation of tumor therapies in preclinical animal models. MAGMA 2004; 17:249-259.
20. Paul OK, Lin AE, Christina Y, et al. Bioluminescent detection of p53 activity response to chemotherapeutic agents. AACR Apoptosis and Cancer Meeting 2/02.
21. Tokalov SV, Abramyuk AM, Abolmaali ND. Protection of p53 wild type cells from taxol by genistein in the combined treatment of lung cancer. Nutr Cancer 2010; 62:795-801.
22. Pajic M, Kerbergen A, Van Diepen F, et al. Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo. Cell Cycle 2010; 9:3780-3791.
23. Rottenberg S, Nygren AO, Pajic M, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 2007; 104:12117-12122.
24. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104:263-269.
25. Pestell KE, Hobbs SM, Titley JC, Kelland LR, Walton MI. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol 2000; 57:503-511.
26. Attardi LD, de Vries A, Jacks T. Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. Oncogene 2004; 23:973-980.
27. Kosmider B, Wojcik I, Osiecka R, et al. Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP. Invest New Drugs 2005; 23:287-297.
28. Guntur VP, Waldrep JC, Guo JJ, Selting K, Dhand R. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. Anticancer Res 2010; 30:3557-3564.
29. Lin X, Ramamurthi K, Mishima M, Kondo A, Howell SB. p53 Interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxide. Mol Pharmacol 2000; 58:1222-1229.
30. Raj K, Ogston P, Beard P. Virus-mediated killing of cells that lack p53 activity. Nature 2001; 412:914-917.
31. Radhakrishnan SK, Feliciano CS, Najmabadi F, et al. Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle. Oncogene 2004; 23:4173-4176.
32. Monte M, Benetti R, Buscemi G, Sandy P, Del Sal G, Schneider C. The cell cycle-regulated protein human GTSE-1 controls DNA damage-induced apoptosis by affecting p53 function. J Biol Chem 2003; 278:30356-30364.
33. Monte M, Benetti R, Buscemi G, Sandy P, Del Sal G, Schneider C. hGTSE-1 expression stimulates cytoplasmic localization of p53. J Biol Chem 2004; 279:11744-11752.
34. Zhou R, Acton PD, Ferrari VA. Imaging stem cells implanted in infarcted myocardium. J Am Coll Cardiol 2006; 48:2094-2106.
35. Craft N, Bruhn KW, Nguyen BD, et al. Bioluminescent imaging of melanoma in live mice. J Invest Dermatol 2005; 125:159-165.